Frontotemporal Dementia and Progranulin Mutation Disorders
Aviadobio Limited’s clinical research activity is centered on frontotemporal dementia with progranulin mutations (FTD-GRN), a genetic form of neurodegenerative disease associated with progressive impairment of behaviour, language, and cognitive function.
- FTD-GRN
- Progranulin deficiency
- Neurodegeneration
The sponsor’s research interest lies in genetically defined dementia and the neurological consequences of GRN-related disease.
Neurological Gene Therapy
The trial portfolio reflects a focus on gene-based therapeutic approaches for central nervous system disorders, with particular attention to treatments designed to address the underlying biology of protein haploinsufficiency in FTD-GRN.
- Gene therapy
- Central nervous system
- Protein replacement strategy
This area places the sponsor within the field of neurological precision medicine for inherited disease.
Intrathalamic Neuromedicine
Research activity also involves intrathalamic administration, highlighting interest in targeted delivery to deep brain structures relevant to neurological intervention and regional CNS delivery.
- Thalamic delivery
- Targeted brain administration
- Neurosurgical delivery
The sponsor’s clinical work is aligned with site-specific treatment strategies for disorders affecting the frontal and temporal lobes.
Rare Neurodegenerative Disease
Aviadobio Limited is active in the therapeutic area of rare neurological disease, with emphasis on conditions that combine genetic causation, progressive cognitive decline, and behavioral symptoms.
- Rare disease neurology
- Cognitive impairment
- Behavioral neurology
This focus connects the sponsor to clinical development in orphan neurodegenerative disorders.
